President Trump may like to use the bully pulpit to call on drug makers to lower their prices, but most Americans don’t believe his tough talk will make much of a difference.

To be specific, 55 percent of Americans say his strategy of publicly calling on drug companies to lower their costs will not be too effective or at all effective, according to a poll by the Kaiser Family Foundation. By comparison, 42 percent say this approach will be very or somewhat effective.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Methinks our venerable scribe could have economized on ink in the title to this post – “Most Americans don’t believe Trump’s tough talk” would have been quite sufficient.
    It might even have generated more clicks from the non-pharma crowd while still being …. accurate.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy